Evidence map›Paper›PMID 32110861›Full record

ReviewNutrients2020

Effects of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on Lipoprotein Atherogenicity.

Marta Farràs, Marina Canyelles, Montserrat Fitó, Joan Carles Escolà-Gil

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Fatty Acids and Protein Content of Underexplored Tropical Palm Fruits.Plant foods for human nutrition (Dordrecht, Netherlands) · 2026
    Article
  3. Article
  4. Article
  5. Multidimensional determinants of active and healthy aging trajectories: a position paper from the Age-It Research Program.The journals of gerontology. Series B, Psychological sciences and social sciences · 2025
    Article
  6. Review
  7. Article
  8. Role of Olive Bioactive Compounds in Respiratory Diseases.Antioxidants (Basel, Switzerland) · 2023
    Review
  9. Review
  10. Alleviation of Malathion Toxicity Effect byPlants (Basel, Switzerland) · 2021
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Marta FarràsMolecular Bases of Cardiovascular Risk Group Institut de Recerca de l'Hospital Santa Creu i Sant Pau-Institut d'Investigacions Biomèdiques (IIB) Sant Pau, 08041 Barcelona, Spain.
Marina CanyellesMolecular Bases of Cardiovascular Risk Group Institut de Recerca de l'Hospital Santa Creu i Sant Pau-Institut d'Investigacions Biomèdiques (IIB) Sant Pau, 08041 Barcelona, Spain.
Montserrat FitóCardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Joan Carles Escolà-GilMolecular Bases of Cardiovascular Risk Group Institut de Recerca de l'Hospital Santa Creu i Sant Pau-Institut d'Investigacions Biomèdiques (IIB) Sant Pau, 08041 Barcelona, Spain.
Instituto de Salud Carlos III · ESUniversitat Autònoma de Barcelona · ES

Funding

FEDER "Una manera de hacer Europa" (ISCIII)Instituto de Salud Carlos III CIBERDEM and CIBEROBNInstituto de Salud Carlos III FIS 16-00139Instituto de Salud Carlos III FIS 19-00136Instituto de Salud Carlos III Sara Borrell contract (CD17/00233)
6 · The paper itself

Abstract

The atherogenicity of low-density lipoprotein (LDL) and triglyceride-rich lipoproteins (TRLs) may be more significant than LDL cholesterol levels. Clinical trials which have led to increased high-density lipoprotein (HDL) cholesterol have not always seen reductions in cardiovascular disease (CVD). Furthermore, genetic variants predisposing individuals to high HDL cholesterol are not associated with a lower risk of suffering a coronary event, and therefore HDL functionality is considered to be the most relevant aspect. Virgin olive oil (VOO) is thought to play a protective role against CVD. This review describes the effects of VOO and phenol-enriched VOOs on lipoprotein atherogenicity and HDL atheroprotective properties. The studies have demonstrated a decrease in LDL atherogenicity and an increase in the HDL-mediated macrophage cholesterol efflux capacity, HDL antioxidant activity, and HDL anti-inflammatory characteristics after various VOO interventions. Moreover, the expression of cholesterol efflux-related genes was enhanced after exposure to phenol-enriched VOOs in both post-prandial and sustained trials. Improvements in HDL antioxidant properties were also observed after VOO and phenol-enriched VOO interventions. Furthermore, some studies have demonstrated improved characteristics of TRL atherogenicity under postprandial conditions after VOO intake. Large-scale, long-term randomized clinical trials, and Mendelian analyses which assess the lipoprotein state and properties, are required to confirm these results.

Indexed as

AnimalsAntioxidantsAtherosclerosisClinical Trials as TopicHumansLipoproteinsOlive OilPhenolsAntioxidantsLipoproteinsOlive OilPhenolschylomicronshigh density lipoproteinlow density lipoproteintriglyceride-rich lipoproteinvirgin olive oil

Identifiers

PMID32110861
PMCPMC7146215
OpenAlexW3008964000

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.